X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Phase 1 study Showed that setanaxib is well tolerated at the doses tested, with no safety signal or dose-limiting toxicity being identified. The study assessed the safety and pharmacokinetics of oral setanaxib at select doses in 46 healthy adult male and female subjects.
Lead Product(s): Setanaxib
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: GKT137831
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2021
Details:
Transaction adds orphan pipeline asset and platform in inflammation and fibrosis. Genkyotex’s lead clinical candidate, setanaxib, is in development for Primary Biliary Cholangitis.
Lead Product(s): Setanaxib
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: GKT831
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Genkyotex
Deal Size: $37.7 million Upfront Cash: Undisclosed
Deal Type: Acquisition August 13, 2020
Details:
This Phase 1 study will evaluate setanaxib at doses up to 1600 mg/day in up to 54 subjects. Genkyotex is currently discussing the registration strategy for setanaxib in PBC with FDA and EMA.
Lead Product(s): Setanaxib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
